<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29661" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sugammadex</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chandrasekhar</surname>
            <given-names>Kaarthik</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Togioka</surname>
            <given-names>Brandon M.</given-names>
          </name>
          <aff>Oregon Health &#x00026; Science University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jeffers</surname>
            <given-names>Jeremiah L.</given-names>
          </name>
          <aff>WVU Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kaarthik Chandrasekhar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brandon Togioka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeremiah Jeffers declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29661.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sugammadex is a modified gamma-cyclodextrin that is used to reverse steroidal non-depolarizing neuromuscular blocking drugs rocuronium and vecuronium. Residual neuromuscular blockade is common after surgery, with an estimated 30 to 60% incidence in the recovery room. The low-level neuromuscular blockade, lower than what can be observed with the naked eye, has been linked to hypoxia, supralaryngeal muscle weakness that predisposes to upper airway obstruction, impaired swallowing, and an increased risk for aspiration. Sugammadex increases the speed of neuromuscular blockade reversal and greatly reduces the risk for residual neuromuscular paralysis. It does not inhibit acetylcholinesterase-like traditional reversal agents, such as neostigmine; therefore, using an antimuscarinic agent such as glycopyrrolate is unnecessary. This activity outlines the indications, mechanisms of action, methods of administration, important adverse effects, contraindications, and monitoring, of sugammadex, so providers can direct patient therapy in treating indicated disorders as part of the interprofessional team with a basis on the current knowledge for optimal utilization.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of sugammadex.</p></list-item><list-item><p>Review the indicated uses for sugammadex.</p></list-item><list-item><p>Describe the potential adverse effects of sugammadex.</p></list-item><list-item><p>Summarize how interprofessional coordination can improve surgical outcomes with sugammadex use.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29661&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29661">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29661.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Sugammadex is a modified gamma-cyclodextrin designed for optimal encapsulation of the neuromuscular blocking drug rocuronium, preventing rocuronium from acting at the acetylcholine receptor.<xref ref-type="bibr" rid="article-29661.r1">[1]</xref>&#x000a0;Though not designed to bind vecuronium, sugammadex also binds and rapidly reverses vecuronium-induced neuromuscular blockade.<xref ref-type="bibr" rid="article-29661.r2">[2]</xref>&#x000a0;Sugammadex carries a Food and Drug Administration approval for antagonism of both rocuronium- and vecuronium-induced neuromuscular blockade in adults.<xref ref-type="bibr" rid="article-29661.r3">[3]</xref></p>
      </sec>
      <sec id="article-29661.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sugammadex contains eight identical hydroxyl chains bound together to create a ring with a hydrophobic core and a hydrophilic outer surface.<xref ref-type="bibr" rid="article-29661.r1">[1]</xref>&#x000a0;The three-dimensional structure of sugammadex resembles a doughnut. The core of sugammadex is large enough to fit the aminosteroid non-depolarizing neuromuscular blocking drugs (NMBDs) rocuronium and vecuronium inside. Once inside, non-covalent hydrophobic interactions secure the NMBD to form water-soluble inclusion complexes.<xref ref-type="bibr" rid="article-29661.r4">[4]</xref>&#x000a0;</p>
        <p>The sugammadex-rocuronium inclusion complex has a very high association constant (1.79 x 10 mol/L).<xref ref-type="bibr" rid="article-29661.r5">[5]</xref>&#x000a0;Higher association constants mean the affinity between molecules is greater. Using this association constant, it has been calculated that the ratio of sugammadex-rocuronium inclusion complexes to sugammadex-rocuronium dissociations is 25 million to 1.<xref ref-type="bibr" rid="article-29661.r6">[6]</xref>&#x000a0;Thus, once rocuronium is bound to sugammadex, it can be considered irreversibly fixed. The sugammadex-vecuronium complex has a 3-fold lower association constant (5.72 x 10 mol/L) compared to sugammadex-rocuronium.<xref ref-type="bibr" rid="article-29661.r5">[5]</xref>&#x000a0;However, vecuronium is six times more potent than rocuronium and is administered in lower doses.<xref ref-type="bibr" rid="article-29661.r5">[5]</xref>&#x000a0;The encapsulation of NMBD by sugammadex occurs in a 1&#x000a0;to 1 ratio. Thus, the lower sugammadex-vecuronium complex association constant is balanced against the need to encapsulate fewer molecules. In conclusion, sugammadex is equally effective at antagonizing vecuronium-induced neuromuscular blockade and rocuronium-induced neuromuscular blockade.<xref ref-type="bibr" rid="article-29661.r2">[2]</xref><xref ref-type="bibr" rid="article-29661.r7">[7]</xref></p>
        <p>Sugammadex reverses neuromuscular blockade by encapsulating free NMBD in plasma. This decreases the plasma concentration of free NMBD, which creates a concentration gradient between the muscle tissue compartment and plasma. Consequently, free NMBD moves from the muscle tissue compartment to plasma; these NMBD are encapsulated by plasma sugammadex, which maintains the lower concentration of free NMBD in plasma and fuels the cycle. Consequently, there is a rapid decrease in the concentration of NMBD at the nicotinic acetylcholine receptor within the neuromuscular junction. This allows neuromuscular activity to resume.<xref ref-type="bibr" rid="article-29661.r8">[8]</xref>&#x000a0;Sugammadex does not inhibit acetylcholinesterase-like traditional reversal agents, such as neostigmine; therefore, co-administration of an antimuscarinic drug such as glycopyrrolate is unnecessary.<xref ref-type="bibr" rid="article-29661.r9">[9]</xref></p>
      </sec>
      <sec id="article-29661.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Administration of sugammadex from 2 mg/kg to 16 mg/kg demonstrates a linear and dose-dependent pharmacokinetic relationship, with an elimination half-life of 100 to 150 minutes and near 100% renal clearance.<xref ref-type="bibr" rid="article-29661.r10">[10]</xref><xref ref-type="bibr" rid="article-29661.r11">[11]</xref>&#x000a0;Since sugammadex acts by forming complexes at a 1:1 ratio, a higher dose of sugammadex is required to antagonize a greater depth of neuromuscular blockade: 2 mg/kg for reversal of moderate neuromuscular blockade (two&#x000a0;twitches in response to train-of-four stimulation), 4 mg/kg for deep blockade (one to two post-tetanic counts after a 5 second 50-hertz tetany), and 16 mg/kg for immediate reversal following an intubating dose of rocuronium (1.2 mg/kg).<xref ref-type="bibr" rid="article-29661.r12">[12]</xref>&#x000a0;Recovery from a 2 or 4 mg/kg dose of sugammadex is significantly faster than antagonism with neostigmine, allowing the achievement of a train-of-four ratio &#x0003e; 0.9 in an average of 3 minutes. Furthermore, sugammadex can reverse deep block faster than neostigmine can reverse moderate block.<xref ref-type="bibr" rid="article-29661.r13">[13]</xref></p>
        <p>While vecuronium and rocuronium should be dosed according to ideal body weight, sugammadex should be dosed according to actual body weight. For obese patients, the use of ideal body weight is likely not enough to achieve full reversal from rocuronium.<xref ref-type="bibr" rid="article-29661.r14">[14]</xref><xref ref-type="bibr" rid="article-29661.r15">[15]</xref></p>
        <p>A few options for reinitiating neuromuscular blockade after administering sugammadex&#x000a0;include redosing rocuronium or vecuronium, succinylcholine, or administering a neuromuscular blocking drug from the benzylisoquinoline class. The company that manufactures sugammadex recommends a minimum waiting period of 5 minutes before administering a 1.2 mg/kg dose of rocuronium and a minimum waiting period of 4 hours before administering a 0.6 mg/kg dose of rocuronium or a 0.1 mg/kg dose of vecuronium. The product insert for sugammadex warms that patients receiving a 1.2 mg/kg dose of rocuronium within 30 minutes of reversal are likely to experience delayed onset and shortened duration of neuromuscular blockade. For patients that receive a 16 mg/kg dose of sugammadex, a minimum wait time of 24 hours is likely needed.</p>
        <p>Sugammadex does not bind to succinylcholine or benzylisoquinoline neuromuscular blocking drugs such as mivacurium, atracurium, and cisatracurium.<xref ref-type="bibr" rid="article-29661.r9">[9]</xref>&#x000a0;The succinylcholine-induced neuromuscular blockade is delayed when administered after sugammadex. Conversely, the cisatracurium-induced neuromuscular blockade has been shown to have a faster onset and results in a deeper level of a block when administered after sugammadex.<xref ref-type="bibr" rid="article-29661.r9">[9]</xref></p>
      </sec>
      <sec id="article-29661.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most commonly reported adverse reactions after sugammadex administration is nausea and vomiting, headache, itching, procedural pain, and dysgeusia.<xref ref-type="bibr" rid="article-29661.r16">[16]</xref><xref ref-type="bibr" rid="article-29661.r17">[17]</xref>&#x000a0;</p>
        <p>Bradycardia has been noted after sugammadex administration, with some reports of cardiac arrest.<xref ref-type="bibr" rid="article-29661.r18">[18]</xref>&#x000a0;In the package insert and subsequent briefing documents, the manufacturer clearly disclosed that bradycardia is a known side effect of sugammadex. The etiology of sugammadex-associated bradycardia is unknown, though there are reports of QT prolongation after sugammadex administration.<xref ref-type="bibr" rid="article-29661.r11">[11]</xref>&#x000a0;Anticholinergics such as atropine have been administered to counteract marked bradycardia and prevent cardiovascular collapse. It is recommended that vasoactive drugs such as epinephrine and atropine be available whenever sugammadex is administered.</p>
        <p>Though more of a characteristic of rapid recovery from neuromuscular blockade than a side effect, surgeons have noticed that patients under light anesthesia may start to cough or move when sugammadex is administered. Bronchospasm after the administration of sugammadex has been reported&#x02014;the incidence appears to be quite low.<xref ref-type="bibr" rid="article-29661.r16">[16]</xref><xref ref-type="bibr" rid="article-29661.r19">[19]</xref></p>
      </sec>
      <sec id="article-29661.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Sugammadex is contraindicated for patients with a history of hypersensitivity reactions, ranging from isolated skin reactions to anaphylaxis. In a study conducted by the manufacturer, the incidence of hypersensitivity in patients with given doses of placebo, 4 mg/kg, or 16 mg/kg was 1%, 7%, and 9%, respectively.</p>
        <p>Patients with a creatinine clearance of less than 30 mL/min are currently not considered candidates for sugammadex. Plasma clearance and urinary excretion of rocuronium and sugammadex are significantly decreased in patients with a creatinine clearance of &#x0003c; 30 ml/min.<xref ref-type="bibr" rid="article-29661.r20">[20]</xref>&#x000a0; Patients with renal failure should be monitored closely if the decision to give sugammadex is made. Sugammadex, as well as sugammadex-rocuronium complexes, can be effectively cleared by hemodialysis.<xref ref-type="bibr" rid="article-29661.r21">[21]</xref></p>
        <p>The remaining contraindications should be considered relative. Therefore, the decision to administer sugammadex should be determined on a patient-by-patient basis after weighing individual risks and benefits.</p>
        <p>Few studies have been conducted on children. The recommended doses for adults appear to be equally efficacious and safe in children.<xref ref-type="bibr" rid="article-29661.r22">[22]</xref>&#x000a0;The manufacturer&#x02019;s official stance is that sugammadex is not approved for administration to patients&#x000a0;under 18 years of age.</p>
        <p>There is very little information regarding the use of sugammadex in pregnant patients. Sugammadex appears to be effective and has a low maternal side effect profile when administered during cesarean delivery.<xref ref-type="bibr" rid="article-29661.r23">[23]</xref><xref ref-type="bibr" rid="article-29661.r24">[24]</xref>&#x000a0;Sugammadex may predispose to skeletal teratogenicity. There has not been evidence of teratogenicity in humans administered up to 16 mg/kg or in rats administered six times the maximum recommended human dose (16 mg/kg). However, pregnant rabbits administered sugammadex at double the maximum recommended human dose delivered low birth weight progeny. In addition, progeny born to pregnant rabbits administered sugammadex at eight times the maximum recommended human dose had incomplete foot and sternum ossification. It is plausible that sugammadex caused this incomplete ossification. Sugammadex has been shown to remain in areas of active mineralization long after it has been eliminated from plasma&#x02014;the half-life of sugammadex in bone is 172 days.</p>
        <p>The use of sugammadex in breastfeeding&#x000a0;patients is likely safe, but there is insufficient data to understand the effect on milk letdown, breastfeeding success, and fetal safety. While it is unknown if the drug is secreted into human breast milk, the likelihood of effects on the infant is low. In one study, sugammadex was present in rat milk, with the maximum drug level occurring 30 minutes after intravenous administration. The Drug and Lactation Database currently states that fetal exposure to sugammadex through breast milk is likely to be low and that sugammadex administration to breastfeeding women is acceptable.<xref ref-type="bibr" rid="article-29661.r25">[25]</xref></p>
        <p>Patients taking hormonal birth control to prevent pregnancy should consider nonhormonal alternatives for&#x000a0;one week after exposure to sugammadex. Sugammadex can bind to progesterone and decrease the effectiveness of hormone-based contraception. Receiving a single dose of sugammadex has been stated to be similar to missing one dose of birth control containing estrogen or progesterone. Therefore, it is recommended that institutions develop a standard handout describing the effect of sugammadex on hormone contraception and recommend additional barrier contraception for seven days following surgery.</p>
      </sec>
      <sec id="article-29661.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Reoccurrence of, or residual neuromuscular blockade, is possible when sugammadex is underdosed.<xref ref-type="bibr" rid="article-29661.r16">[16]</xref><xref ref-type="bibr" rid="article-29661.r26">[26]</xref>&#x000a0;It is now considered best practice to utilize quantitative neuromuscular monitoring with a device such as an electromyograph or acceleromyograph to avoid the underdosing of sugammadex.<xref ref-type="bibr" rid="article-29661.r27">[27]</xref>&#x000a0;Patients who take the medications toremifene (an estrogen receptor modulator) or fusidic acid (an antibiotic) require monitoring for possible prolonged neuromuscular blockade. Toremifene and fusidic acid have a high affinity for sugammadex, leading to the possible displacement of rocuronium or vecuronium from the sugammadex molecule.<xref ref-type="bibr" rid="article-29661.r28">[28]</xref></p>
        <p>Through in vitro and in vivo studies, it has been established that sugammadex can prolong the prothrombin time (PT) and the activated partial thromboplastin time (aPTT). In a study conducted by the drug manufacturer, healthy volunteers receiving 4 to 16 mg/kg of sugammadex demonstrated a 25% prolongation in aPTT and PT that lasted for 1 hour. However, this laboratory coagulopathy has not translated to more bleeding events or a higher incidence of anemia during surgery.<xref ref-type="bibr" rid="article-29661.r29">[29]</xref>&#x000a0;It has been hypothesized that the prolongation in PT and aPTT are seen after sugammadex administration may be an in vitro artifact.<xref ref-type="bibr" rid="article-29661.r30">[30]</xref>&#x000a0;In vitro experiments have demonstrated a further prolongation of PT and PTT when Sugammadex is administered in combination with unfractionated heparin, low molecular weight heparin, warfarin, rivaroxaban, and dabigatran. Accordingly, extra caution is necessary when administering sugammadex to patients taking anticoagulant medications.</p>
      </sec>
      <sec id="article-29661.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Sugammadex is biologically inactive and is generally well tolerated. However, concerns related to anaphylaxis caused the Food and Drug Administration to delay approval for sugammadex for years. An early&#x000a0;manufacturer-sponsored study found a 0.3% incidence of anaphylaxis. The study involved 299 subjects, and one subject who received the largest dose, 16 mg/kg, had an anaphylactic reaction. Sugammadex has been approved in the United States since 2015, in Japan since 2010, and in the European Union since 2008. The actual rate of anaphylaxis appears to be much lower, perhaps similar to the incidence of anaphylaxis from rocuronium.<xref ref-type="bibr" rid="article-29661.r31">[31]</xref><xref ref-type="bibr" rid="article-29661.r32">[32]</xref>&#x000a0;Reassuringly, anaphylaxis does not seem to be more common with repeated exposure. The risk of anaphylaxis appears to be higher when higher doses are administered. The most common clinical symptoms of anaphylaxis are skin changes (flushing, rash, erythema, and urticaria) and hypotension.</p>
      </sec>
      <sec id="article-29661.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>It is now undisputed that sugammadex provides a faster and more complete reversal of neuromuscular blockade than neostigmine. However, for most institutions, sugammadex remains more expensive than neostigmine. Therefore, there is significant international interest in determining if the increased cost of sugammadex can be offset by increased operating room efficiency, better surgical outcomes, shorter recovery room times, fewer postoperative complications, and reduced hospital readmission rates.</p>
        <p>Residual neuromuscular blockade is common after surgery, with an estimated 30&#x000a0;to 60% incidence in the recovery room.<xref ref-type="bibr" rid="article-29661.r33">[33]</xref>&#x000a0;The low-level neuromuscular blockade, lower than what can be observed with the naked eye, has been linked to hypoxia,&#x000a0;supralaryngeal muscle weakness that predisposes to upper airway obstruction,&#x000a0;impaired swallowing,&#x000a0;and an increased risk for aspiration.<xref ref-type="bibr" rid="article-29661.r34">[34]</xref>&#x000a0;Sugammadex increases the speed of neuromuscular blockade reversal and greatly reduces the risk for residual neuromuscular paralysis. Faster antagonism of neuromuscular blockade from sugammadex has been linked to a shorter time interval between neuromuscular blockade antagonism to operating room discharge&#x000a0;and a lower 30-day hospital readmission rate.<xref ref-type="bibr" rid="article-29661.r35">[35]</xref><xref ref-type="bibr" rid="article-29661.r36">[36]</xref></p>
        <p>Evidence is emerging that sugammadex may reduce the risk of postoperative pulmonary complications. Single-institution interrupted time series analysis&#x000a0;and a large multi-institution retrospective matched cohort study found a lower rate of postoperative pulmonary complications with sugammadex than neostigmine.<xref ref-type="bibr" rid="article-29661.r37">[37]</xref>&#x000a0;Prospective, randomized, controlled trials have not found a difference in the incidence of postoperative pulmonary complications after administering sugammadex compared to neostigmine.<xref ref-type="bibr" rid="article-29661.r38">[38]</xref>&#x000a0;However, it is widely believed these studies were underpowered.&#x000a0;</p>
        <p>There is budding interest in determining if sugammadex may help reduce the incidence of postoperative ileus. The incidence of postoperative ileus after colorectal surgery has been reported to be 10&#x000a0;to 25%.<xref ref-type="bibr" rid="article-29661.r39">[39]</xref><xref ref-type="bibr" rid="article-29661.r40">[40]</xref>&#x000a0;The alternative neuromuscular blockade antagonism regimen to sugammadex, neostigmine, and glycopyrrolate impact bowel function. Sugammadex does not bind to acetylcholine receptors in the bowel and appears not to affect bowel function. Retrospective studies have found that sugammadex is associated with a faster time to first bowel movement and fewer ileus-related delays in hospital discharge.<xref ref-type="bibr" rid="article-29661.r41">[41]</xref><xref ref-type="bibr" rid="article-29661.r42">[42]</xref>&#x000a0;Conversely, two randomized, controlled trials found no difference in time to first bowel movement or rate of postoperative ileus.<xref ref-type="bibr" rid="article-29661.r43">[43]</xref>&#x000a0;Future investigation is needed to determine if sugammadex has a role in speeding up the recovery of bowel function and reducing the rate of postoperative ileus.</p>
        <p>In summary, sugammadex is a valuable tool to reverse neuromuscular blockade administered to perform many procedures and surgeries. Still, for safe and effective use, it requires the efforts of an interprofessional team, including clinicians, surgeons, specialists, anesthesiologists/nurse anesthetists, surgical nurses, and pharmacists. An interprofessional approach will improve patient outcomes and fewer adverse events when using sugammadex in situations where it has been indicated. [Level 5]</p>
      </sec>
      <sec id="article-29661.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29661&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29661">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29661/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29661">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29661.s11">
        <title>References</title>
        <ref id="article-29661.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gijsenbergh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ramael</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Houwing</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Iersel</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.</article-title>
            <source>Anesthesiology</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>695</fpage>
            <page-range>695-703</page-range>
            <pub-id pub-id-type="pmid">16192761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morias</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cammu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Duijnhoven</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Heeringa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demeyer</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.</article-title>
            <source>Anesthesiology</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>283</fpage>
            <page-range>283-8</page-range>
            <pub-id pub-id-type="pmid">17264722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex approved to reverse NMBA effects.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2016</year>
            <month>Feb</month>
            <day>01</day>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>100</fpage>
            <pub-id pub-id-type="pmid">26796899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cameron</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fielding</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MQ</given-names>
              </name>
            </person-group>
            <article-title>Modified gamma-cyclodextrins and their rocuronium complexes.</article-title>
            <source>Org Lett</source>
            <year>2002</year>
            <month>Oct</month>
            <day>03</day>
            <volume>4</volume>
            <issue>20</issue>
            <fpage>3403</fpage>
            <page-range>3403-6</page-range>
            <pub-id pub-id-type="pmid">12323029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asztalos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Szab&#x000f3;-Ma&#x000e1;k</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gajdos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nemes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pongr&#x000e1;cz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lengyel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>F&#x000fc;lesdi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tassonyi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Reversal of Vecuronium-induced Neuromuscular Blockade with Low-dose Sugammadex at Train-of-four Count of Four: A Randomized Controlled Trial.</article-title>
            <source>Anesthesiology</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>127</volume>
            <issue>3</issue>
            <fpage>441</fpage>
            <page-range>441-449</page-range>
            <pub-id pub-id-type="pmid">28640017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nag</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Shetti</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sivashanmugam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parthasarathy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex: A revolutionary drug in neuromuscular pharmacology.</article-title>
            <source>Anesth Essays Res</source>
            <year>2013</year>
            <season>Sep-Dec</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>302</fpage>
            <page-range>302-6</page-range>
            <pub-id pub-id-type="pmid">25885973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khuenl-Brady</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Wattwil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vanacker</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Lora-Tamayo</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Rietbergen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alvarez-G&#x000f3;mez</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.</article-title>
            <source>Anesth Analg</source>
            <year>2010</year>
            <month>Jan</month>
            <day>01</day>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-73</page-range>
            <pub-id pub-id-type="pmid">19713265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epemolu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969.</article-title>
            <source>Anesthesiology</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>99</volume>
            <issue>3</issue>
            <fpage>632</fpage>
            <page-range>632-7; discussion 6A</page-range>
            <pub-id pub-id-type="pmid">12960547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naguib</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex: another milestone in clinical neuromuscular pharmacology.</article-title>
            <source>Anesth Analg</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>104</volume>
            <issue>3</issue>
            <fpage>575</fpage>
            <page-range>575-81</page-range>
            <pub-id pub-id-type="pmid">17312211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000fc;hringer</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demeyer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sparr</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ingimarsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klarin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Duijnhoven</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Heeringa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.</article-title>
            <source>Br J Anaesth</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>105</volume>
            <issue>5</issue>
            <fpage>610</fpage>
            <page-range>610-9</page-range>
            <pub-id pub-id-type="pmid">20876699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000fc;hringer</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Rex</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sielenk&#x000e4;mper</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Claudius</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Eikermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khuenl-Brady</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.</article-title>
            <source>Anesthesiology</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>109</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-97</page-range>
            <pub-id pub-id-type="pmid">18648227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaller</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.</article-title>
            <source>Core Evid</source>
            <year>2013</year>
            <volume>8</volume>
            <fpage>57</fpage>
            <page-range>57-67</page-range>
            <pub-id pub-id-type="pmid">24098155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geldner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Niskanen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laurila</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mizikov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>H&#x000fc;bler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rietbergen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nicolayenko</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.</article-title>
            <source>Anaesthesia</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>67</volume>
            <issue>9</issue>
            <fpage>991</fpage>
            <page-range>991-8</page-range>
            <pub-id pub-id-type="pmid">22698066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llaurad&#x000f3;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sabat&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferreres</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Camprub&#x000ed;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cabrera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery.</article-title>
            <source>Anesthesiology</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-8</page-range>
            <pub-id pub-id-type="pmid">22549697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Lancker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dillemans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bogaert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mulier</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>De Kock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haspeslagh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients.</article-title>
            <source>Anaesthesia</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>66</volume>
            <issue>8</issue>
            <fpage>721</fpage>
            <page-range>721-5</page-range>
            <pub-id pub-id-type="pmid">21692760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Togioka</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Yanez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tekkali</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Treggiari</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery.</article-title>
            <source>Br J Anaesth</source>
            <year>2020</year>
            <month>May</month>
            <volume>124</volume>
            <issue>5</issue>
            <fpage>553</fpage>
            <page-range>553-561</page-range>
            <pub-id pub-id-type="pmid">32139135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flockton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mastronardi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gomar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mirakhur</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Aguilera</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giunta</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Meistelman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.</article-title>
            <source>Br J Anaesth</source>
            <year>2008</year>
            <month>May</month>
            <volume>100</volume>
            <issue>5</issue>
            <fpage>622</fpage>
            <page-range>622-30</page-range>
            <pub-id pub-id-type="pmid">18385265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Naguib</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex-induced bradycardia and asystole: how great is the risk?</article-title>
            <source>Br J Anaesth</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-12</page-range>
            <pub-id pub-id-type="pmid">29935599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baronos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Selvaraj</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yarmush</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex-induced bronchospasm during desflurane anaesthesia.</article-title>
            <source>Br J Anaesth</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>e155</fpage>
            <page-range>e155-e156</page-range>
            <pub-id pub-id-type="pmid">31027913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staals</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Snoeck</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Driessen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van Hamersvelt</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Flockton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.</article-title>
            <source>Br J Anaesth</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-9</page-range>
            <pub-id pub-id-type="pmid">20007792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cammu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Van Vlem</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>el Galta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eloot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demeyer</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment.</article-title>
            <source>Br J Anaesth</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-90</page-range>
            <pub-id pub-id-type="pmid">22732111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plaud</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meretoja</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hofmockel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stoddart</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>van Kuijk</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hermens</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mirakhur</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.</article-title>
            <source>Anesthesiology</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>110</volume>
            <issue>2</issue>
            <fpage>284</fpage>
            <page-range>284-94</page-range>
            <pub-id pub-id-type="pmid">19194156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000fc;hringer</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rex</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex reversal of rocuronium-induced neuromuscular block in Caesarean section patients: a series of seven cases.</article-title>
            <source>Br J Anaesth</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>105</volume>
            <issue>5</issue>
            <fpage>657</fpage>
            <page-range>657-60</page-range>
            <pub-id pub-id-type="pmid">20736231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nauheimer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kollath</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Geldner</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Modified rapid sequence induction for Caesarian sections : case series on the use of rocuronium and sugammadex].</article-title>
            <source>Anaesthesist</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>691</fpage>
            <page-range>691-5</page-range>
            <pub-id pub-id-type="pmid">22875060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <chapter-title>Sugammadex</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotake</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ochiai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakatsuka</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.</article-title>
            <source>Anesth Analg</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>117</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-51</page-range>
            <pub-id pub-id-type="pmid">23757472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naguib</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brull</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kopman</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>F&#x000fc;lesdi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arkes</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Elstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Consensus Statement on Perioperative Use of Neuromuscular Monitoring.</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-80</page-range>
            <pub-id pub-id-type="pmid">29200077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zwiers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smeets</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach.</article-title>
            <source>Clin Drug Investig</source>
            <year>2011</year>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-11</page-range>
            <pub-id pub-id-type="pmid">21067251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moon</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Jun</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of postoperative coagulation profiles and outcome for sugammadex versus pyridostigmine in 992 living donors after living-donor hepatectomy.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>11</issue>
            <fpage>e0129</fpage>
            <pub-id pub-id-type="pmid">29538210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dirkmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Britten</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Pauling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weidle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Volbracht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>G&#x000f6;rlinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulant Effect of Sugammadex: Just an In Vitro Artifact.</article-title>
            <source>Anesthesiology</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>124</volume>
            <issue>6</issue>
            <fpage>1277</fpage>
            <page-range>1277-85</page-range>
            <pub-id pub-id-type="pmid">26950705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sunaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hobo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Muto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uezono</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Incidence of Anaphylaxis Associated With Sugammadex.</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>May</month>
            <volume>126</volume>
            <issue>5</issue>
            <fpage>1505</fpage>
            <page-range>1505-1508</page-range>
            <pub-id pub-id-type="pmid">29064876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Assaid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCrea</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gurner</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sisk</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Adkinson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Herring</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence of hypersensitivity and anaphylaxis with sugammadex.</article-title>
            <source>J Clin Anesth</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>47</volume>
            <fpage>67</fpage>
            <page-range>67-73</page-range>
            <pub-id pub-id-type="pmid">29621739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brueckmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grobara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Bie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maktabi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kwo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sabouri</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McGovern</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Staehr-Rye</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Eikermann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.</article-title>
            <source>Br J Anaesth</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>743</fpage>
            <page-range>743-51</page-range>
            <pub-id pub-id-type="pmid">25935840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbstreit</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eikermann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impaired upper airway integrity by residual neuromuscular blockade: increased airway collapsibility and blunted genioglossus muscle activity in response to negative pharyngeal pressure.</article-title>
            <source>Anesthesiology</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>1253</fpage>
            <page-range>1253-60</page-range>
            <pub-id pub-id-type="pmid">19417617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zarantonello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lazzarotto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tellaroli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ori</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Role of sugammadex in accelerating postoperative discharge: A meta-analysis.</article-title>
            <source>J Clin Anesth</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>39</volume>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">28494905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jee</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Retrospective analysis of 30-day unplanned readmission after major abdominal surgery with reversal by sugammadex or neostigmine.</article-title>
            <source>Br J Anaesth</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>122</volume>
            <issue>3</issue>
            <fpage>370</fpage>
            <page-range>370-378</page-range>
            <pub-id pub-id-type="pmid">30770055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McWilliams</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Bullard</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Jameson</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Mikulich-Gilbertson</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Fernandez-Bustamante</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartels</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design.</article-title>
            <source>Anesth Analg</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-151</page-range>
            <pub-id pub-id-type="pmid">31702700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alday</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Planas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mata</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial.</article-title>
            <source>Can J Anaesth</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>66</volume>
            <issue>11</issue>
            <fpage>1328</fpage>
            <page-range>1328-1337</page-range>
            <pub-id pub-id-type="pmid">31165457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tevis</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Postoperative Complications: Looking Forward to a Safer Future.</article-title>
            <source>Clin Colon Rectal Surg</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-52</page-range>
            <pub-id pub-id-type="pmid">27582650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asgeirsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>El-Badawi</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luchtefeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Senagore</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Postoperative ileus: it costs more than you expect.</article-title>
            <source>J Am Coll Surg</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>210</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-31</page-range>
            <pub-id pub-id-type="pmid">20113944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deljou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Ballinger</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Sprung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weingarten</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>Effects of Sugammadex on Time of First Postoperative Bowel Movement: A Retrospective Analysis.</article-title>
            <source>Mayo Clin Proc Innov Qual Outcomes</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>294</fpage>
            <page-range>294-301</page-range>
            <pub-id pub-id-type="pmid">31485567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chae</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Joe</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>IK</given-names>
              </name>
            </person-group>
            <article-title>Thirty-Day Postoperative Outcomes Following Sugammadex Use in Colorectal Surgery Patients; Retrospective Study.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>16</day>
            <volume>8</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30654513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29661.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Erdivanli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tomak</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pergel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reversal of neuromuscular blockade with sugammadex or neostigmine/atropine: Effect on postoperative gastrointestinal motility.</article-title>
            <source>J Clin Anesth</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>32</volume>
            <fpage>208</fpage>
            <page-range>208-13</page-range>
            <pub-id pub-id-type="pmid">27290978</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
